FDA’s Advertising Enforcement Turns Its Focus To YouTube, ADHD Drugs
Executive Summary
FDA's spate of five promotional citations to manufacturers of attention deficit/hyperactivity disorder drugs signals that the agency intends to remain vigilant in oversight of new media
You may also be interested in...
Luvox CR Symptom Benefit Claims Draw DDMAC Warning
An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state
Luvox CR Symptom Benefit Claims Draw DDMAC Warning
An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state
Daytrana Approval For Adolescents Gives Shire's ADHD Drug A New Lease On Life
Sales of the patch were down 10 percent last year due to recalls caused by manufacturing problems.